Table 2.
Targeted antibodies for lung cancer therapy
| Targeted Antibodies | Lung cancer type | Related Molecule | Target / Bioactivity |
|---|---|---|---|
| Monoclonal Antibodies (MABs) | NSCLC | Cetuximab | Anti-EGFR |
| Necitumumab | Anti-EGFR | ||
| Nimotuzumab | Anti-EGFR | ||
| Ficlatuzumab | Anti-EGFR | ||
| Bevacizumab | Anti-VEGF | ||
| Ramucirumab | Anti-VEGF/VEGFR2 | ||
| Nivolumab | Anti-PD-1 | ||
| Pembrolizumab | Anti-PD-1 | ||
| Ipilimumab | Anti-CTLA-4 | ||
| Tremelimumab | Anti-CTLA-4 | ||
| Denosumab | Anti-RANKL | ||
| Figitumumab | Anti-IGF-1R | ||
| SCLC | Tarextumab | Anti-Notch2 / Notch3 | |
| Tucotuzumab | Anti-EpCAM | ||
| Bec2 | Anti-GD3 | ||
| Antibody–Drug Conjugate (ADC) | SCLC | Rovalpituzumab tesirine | Anti-DLL3 |
| Sacituzumab govitecan | Anti-Trop-2 | ||
| Lorvotuzumab mertansine | Anti-CD56 | ||
| NSCLC | Ado-Trastuzumab emtansine | Anti-HER2 | |
| Telisotuzumab vedotin | Anti-cMET | ||
| Enapotamab vedotin | Anti-AXL | ||
| Bispecific antibodies | NSCLC | Amivantamab | Anti-EGFR, Anti-MET |